Giovanni Muncipinto

Giovanni Muncipinto is currently the Director of Medicinal Chemistry at Photys. Previously, they worked as an Associate Director at Jnana Therapeutics from February 2017 to July 2022, where they played a key role in the design, synthesis, and SAR of analogs for the development of novel orally bioavailable small molecule inhibitors of IL-17 as part of a collaboration between Ensemble Therapeutics and Novartis. Giovanni also developed efficient synthetic routes towards enantiomerically pure building blocks with multiple stereocenters, resulting in a better understanding of the chemical space and improvement of PK properties. Prior to that, they worked as a Principal Scientist at Ensemble Therapeutics Corporation from December 2014 to November 2016, where they significantly contributed to the Indoleamine 2,3-dioxygenase (IDO) program, from hit validation to the nomination of the development candidate. Giovanni was also the team leader of the series that ultimately generated the development candidate for this program. Additionally, they were the team leader of the Tryptophan 2,3-dioxygenase (TDO) program, where they managed two other scientists in hit validation efforts and then in hit-to-lead process. Prior to that, they worked as a Visiting Researcher at Bayer HealthCare from August 2014 to October 2014.

Giovanni Muncipinto has a PhD in Medicinal Chemistry from Università degli Studi di Bari and a PhD visiting scholar from Harvard University in Organic Chemistry. Giovanni also has an MS in Medicinal Chemistry from Università degli Studi di Bari and a doctorate from Liceo Classico Cagnazzi.

Giovanni Muncipinto reports to Flo Wagner, VP Chemistry Platform. Some of their coworkers include Carolina Romano - Office Manager, Klothilda Lim - Lab Manager, and Dominique Pothin - P. Scientist.